VAM
Visium Asset Management Portfolio holdings
AUM
$955M
This Quarter Return
+10.2%
1 Year Return
-4.5%
3 Year Return
+94.87%
5 Year Return
–
10 Year Return
–
AUM
$6.25B
AUM Growth
+$6.25B
(-9.6%)
Cap. Flow
-$1.02B
Cap. Flow
% of AUM
-16.38%
Top 10 Holdings %
Top 10 Hldgs %
28.47%
Holding
991
New
154
Increased
175
Reduced
155
Closed
445
Top Buys
| 1 |
Brookdale Senior Living
BKD
|
$81.5M |
| 2 |
Elevance Health
ELV
|
$43.4M |
| 3 |
Baxter International
BAX
|
$38.8M |
| 4 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$34.1M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$30.8M |
Top Sells
| 1 |
Bausch Health
BHC
|
$184M |
| 2 |
Perrigo
PRGO
|
$158M |
| 3 |
Cigna
CI
|
$116M |
| 4 |
McKesson
MCK
|
$87.1M |
| 5 |
AET
Aetna Inc
AET
|
$85M |
Sector Composition
| 1 | Healthcare | 54.62% |
| 2 | Financials | 8.65% |
| 3 | Energy | 5.79% |
| 4 | Industrials | 5.48% |
| 5 | Technology | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Elevance Health
ELV
$72B
| $43.4M | 0.65% |
+311,300
| New | +$43.4M |
|
27
Chubb
CB
$110B
| $42.8M | 0.64% |
348,754
-9,826
| -3% | -$1.21M |
|
|
AMRI
28
DELISTED
Albany Molecular Research Inc
AMRI
| $41.7M | 0.63% |
2,098,800
-1,201,200
| -36% | -$23.8M |
|
29
Medifast
MED
$153M
| $41M | 0.62% |
1,350,000
| – | – |
|
|
30
Baxter International
BAX
$12.2B
| $39.4M | 0.59% |
1,033,900
+1,016,396
| +5,807% | +$38.8M |
|
|
31
McKesson
MCK
$85.6B
| $38.8M | 0.58% |
196,504
-441,550
| -69% | -$87.1M |
|
|
PCP
32
DELISTED
PRECISION CASTPARTS CORP
PCP
| $36.3M | 0.55% |
156,655
+4,271
| +3% | +$991K |
|
|
33
Cigna
CI
$79.9B
| $36.2M | 0.54% |
247,582
-790,130
| -76% | -$116M |
|
34
Hartford Financial Services
HIG
$37.3B
| $35.3M | 0.53% |
812,992
+568,477
| +232% | +$24.7M |
|
|
SPNC
35
DELISTED
Spectranetics Corp
SPNC
| $35.1M | 0.53% |
2,327,973
+377,973
| +19% | +$5.69M |
|
|
QTNT
36
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $32.5M | 0.49% |
2,028,149
+355,699
| +21% | +$5.69M |
|
|
BHI
37
DELISTED
Baker Hughes
BHI
| $32.4M | 0.49% |
702,620
+47,596
| +7% | +$2.2M |
|
38
Edwards Lifesciences
EW
$48.1B
| $31.1M | 0.47% |
393,268
+157,826
| +67% | +$12.5M |
|
39
Acadia Pharmaceuticals
ACAD
$4.33B
| $30.9M | 0.46% |
867,117
+5,697
| +0.7% | +$203K |
|
|
40
Teva Pharmaceuticals
TEVA
$21.5B
| $30.8M | 0.46% |
+469,900
| New | +$30.8M |
|
41
Agilent Technologies
A
$35.2B
| $29.7M | 0.45% |
709,191
+503,673
| +245% | +$21.1M |
|
42
Schlumberger
SLB
$52.2B
| $27.2M | 0.41% |
389,604
-133,320
| -25% | -$9.3M |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $26.9M | 0.4% |
1,020,000
| – | – |
|
44
Boston Scientific
BSX
$159B
| $25.9M | 0.39% |
1,404,300
+1,393,000
| +12,327% | +$25.7M |
|
45
Synchrony
SYF
$28B
| $25.7M | 0.39% |
846,571
+831,099
| +5,372% | +$25.3M |
|
|
NVRO
46
DELISTED
NEVRO CORP.
NVRO
| $25.5M | 0.38% |
377,824
+152,405
| +68% | +$10.3M |
|
47
CME Group
CME
$96.4B
| $25.4M | 0.38% |
280,636
+139,636
| +99% | +$12.7M |
|
48
Visa
V
$679B
| $25.2M | 0.38% |
324,761
-29,809
| -8% | -$2.31M |
|
49
Ascendis Pharma
ASND
$12.2B
| $25.1M | 0.38% |
1,370,000
| – | – |
|
50
Universal Insurance Holdings
UVE
$697M
| $24M | 0.36% |
1,034,799
+963,396
| +1,349% | +$22.3M |
|